CAS: 17685-04-0; (2S,3S,4S,5R,6R)-6-Ethoxy-3,4,5-Trihydroxytetrahydro-2H-Pyran-2-Carboxylic Acid

相似化合物

7355-18-2 3082-96-0 154460-56-7

上下游产品

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester methyl (ethyl 2,3,4-tri-O-acetyl-β-D-glucopyranosid)uronate ethanol

📜乙酰溴-Alpha-D-葡萄糖酮酸甲基酯置于甲醇,Sodium Methylate,Silver(L) Oxide体系中,用 乙腈 用作溶剂,化学反应 13.0H,反应生成乙基&beta-D-葡萄糖醛酸
参考文献: Electrochemical Methods And Compounds For The Detection Of Enzymes[fr] Composés Et Procédés électrochimiques Pour La Détection D'Enzymes
标题: Electrochemical Methods And Compounds For The Detection Of Enzymes[fr] Composés Et Procédés électrochimiques Pour La Détection D'Enzymes
摘要:本文揭示了一种用于电化学检测酶的组合物和方法,例如指示疾病,紊乱或病原体(如病毒,细菌和真菌)的酶.这些方法可用于疾病,紊乱或病原体的现场诊断检测(例如,在医疗环境中识别感染患者的病原体菌株).本文描述的电化学方法还可用于评估病原体对抗病原药物的敏感性.还提供了适用于与本文描述的方法结合使用的探针.

专利信息

专利号:EP-4416163-A1
优先权日:2021-10-14
标题:Method for the synthesis of evoc probes

专利号:WO-2023062386-A1
优先权日:2021-10-14
标题 :Method for the synthesis of evoc probes

专利号:WO-2010031875-A1
优先权日:2008-09-22
标题:Drug metabolism
发明人：DRAGAN CALAIN-AUREL; BUCHHEIT DANIELA; BUREIK MATTHIAS
权利人:POMBIO TECH GMBH; DRAGAN CALAIN-AUREL; BUCHHEIT DANIELA; BUREIK MATTHIAS
摘要:The invention relates to the technical area of detoxification and metabolism of drugs as well as endogenous compounds. Particularly, the present invention relates to the physiological and pharmacological significance of glucuronidation and to the biotechnological production of glucuronides. Drug metabolites generated by UDP glycosyltransferases (UGTs) are needed for drug development and toxicity studies, especially in the context of metabolites in safety testing (MIST). Since chemical metabolite synthesis can be stereo chemically demanding and arduous, various biological approaches have been developed; however, no whole-cell biotransformation with recombinant microbes that expresses human UGTs could yet be achieved. In this invention human UDP glucose-6-dehydrogenase was expressed (UGDH) together with a UGT isoform in the fission yeast Schizosaccharomyces pombe and strains that catalyze the whole-cell glucuronidation of standard substrates at rates up to 150 μmol L'1 d'1 were generated. Moreover, two methods to obtain stable isotope-labelled glucuronide metabolites were established: The first makes use of a labelled aglycon, while the second employs 13C6-glucose as a metabolic precursor of isotope-labelled UDP-glucuronic acid (UDP-GA) and yields a sixfold labelled glucuronide. This system should lead to a significant facilitation in the production of both labelled and unlabeled drug glucuronides.